ReviewGastroenterology research and practice2014
COX-2 Inhibitors and Gastric Cancer.
Review in Gastroenterology research and practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis.Oncotarget · 2017Pooled it
- Effects of repeated 14-day oral toxicity of fermentedOpen veterinary journal · 2025Article
- Precancerous pathways to gastric cancer: a review of experimental animal models recapitulating the correa cascade.Frontiers in cell and developmental biology · 2025Review
- Chemopreventive Properties of Black Raspberries and Strawberries in Esophageal Cancer Review.Antioxidants (Basel, Switzerland) · 2022Review
- Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer.World journal of gastrointestinal oncology · 2021Review
- Review
- Celecoxib induces apoptosis through Akt inhibition in 5-fluorouracil-resistant gastric cancer cells.Toxicological research · 2021Article
- Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors.Molecular diversity · 2020Article
- The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.Oncogene · 2020Article
- Overexpression of COX-2 and clinicopathological features of gastric cancer: a meta-analysis.Translational cancer research · 2020Article
- Ethanol extracts ofFood & nutrition research · 2019Article
- The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer.Frontiers in pharmacology · 2019Article
- MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2.Experimental and therapeutic medicine · 2018Article
- Dietary n-3 and n-6 polyunsaturated fatty acids, the FADS gene, and the risk of gastric cancer in a Korean population.Scientific reports · 2018Article
- Transcriptome profiling of cancer tissues in Chinese patients with gastric cancer by high-throughput sequencing.Oncology letters · 2018Article
- NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.PloS one · 2018Article
- Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?American journal of translational research · 2017Article
- Brahma-related gene 1 induces apoptosis in a p53-dependent manner in human rheumatoid fibroblast-like synoviocyte MH7A.Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evidence that cyclooxygenase-2 (COX-2) is upregulated and plays an important role in carcinogenesis of gastric cancer has triggered the topic of COX-2 inhibitors as chemopreventive agents for gastric cancer. Studies find that COX-2 inhibitors are associated not only with chemoprophylactic effects, but also with chemotherapeutic potentials in gastric cancer. Both COX-dependent and COX-independent pathways have a role in the anticancer efficiency of COX-2 inhibitors. However, enthusiasm is thwarted by the potential toxicity, that is, gastrointestinal toxicity of nonselective COX-2 inhibitors and cardiovascular risk of selective COX-2 inhibitors. Therefore, more studies are needed to develop new targeted antitumor agents (such as prostaglandin E receptor antagonist) and to define fundamental questions such as optimal treatment regimens, integration of cotherapy, and careful selection of candidates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.